Industry news that matters to you.  Learn more

Archives for May 2011

Ridge Diagnostics Developing a Blood Test for Depression

Earlier this month at the annual American Psychiatric Association meeting, Ridge Diagnostics described the development of what they believe to be a successful blood screening technique for clinical depression.

Rules-Based Medicine Reaches a Significant Milestone in Companion Diagnostic Program With Roche Milestone Demonstrates Effectiveness of RBM’s Strategic Biomarker Services

Rules-Based Medicine (RBM), a global leader in biomarker testing services, and its subsidiary, Psynova Neurotech, has achieved a significant milestone in a companion diagnostic development program with Roche. Using samples from a Roche clinical trial, the RBM DiscoveryMAP® platform, and Psynova’s biomarker database and expertise, a biomarker pattern was identified that has utility in prognosis of disease progression and/or predicting or monitoring the efficacy for a compound in the Roche CNS pipeline. Roche has exercised its option to continue commercial development based on these results, which could result in additional future milestone and royalty payments to RBM/Psynova.

BG Medicine Announces Achievement of Two Significant Milestones for AMIPredict

BG Medicine, Inc. announced recently that it has successfully completed an important phase in the development of its AMIPredict diagnostic product candidate. AMIPredict is being developed to identify patients with a high risk of suffering heart attack or stroke within the next two to four years. The AMIPredict test is an in vitro diagnostic multivariate index assay that simultaneously measures multiple protein biomarkers in blood. The completed phase of development involved two milestones, the verification of AMIPredict’s performance in a second independent study and the migration of the test from the original discovery platform to an automated, high-throughput platform.

Rules-Based Medicine Acquires Intellectual Property Assets of Satoris, Inc.

Rules-Based Medicine (RBM), a global leader in biomarker testing services, recently announced the acquisition of intellectual property assets from Satoris, Inc. The portfolio is based on extensive research to discover biomarkers and biomarker panels for clinical and research use in the areas of Alzheimer’s disease, frontal temporal dementia, Parkinson’s disease, and other conditions that affect the central nervous system.

ACS Biomarker Closes Financing Round, Appoints New CEO

ACS Biomarker B.V., a Dutch biotechnology company focused on the discovery, validation and commercialization of novel cardiovascular biomarkers announces the closing of a financing round. The investment is made by the Life Sciences Fund Amsterdam and Limburg Ventures. The funding will be used to further develop the product pipeline and discover novel biomarkers that improve diagnosis, prognosis and management of cardiac diseases.